Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) in various hypertensive populations and screen at risk members of GRA pedigrees.
II. Investigate other factors regulating blood pressure in GRA (environmental, genetically determined factors).
III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA.
IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm.
|Study Design:||Primary Purpose: Screening|
|Study Start Date:||June 1999|
Patients are screened for high blood pressure, suppressed plasma renin activity level, and low potassium levels. Urine is collected for a 24 hour period. Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA. Any history of cardiovascular events is recorded.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004354
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Robert G. Dluhy||Brigham and Women's Hospital|